Adolescence, schizophrenia and drug abuse: a window of vulnerability.

Adolescence, schizophrenia and drug abuse: a window of vulnerability. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Adolescence, schizophrenia and drug abuse: a window of vulnerability. Abstract Text:

L van Nimwegen,L de Haan,N van Beveren,W van den Brink,D Linszen,

OBJECTIVE: To discuss the neurobiological and psychosocial developmental factors in adolescence contributing to simultaneous onset and co-occurrence of psychosis and substance use disorders. METHOD: A review of the literature. RESULTS: Adolescence is a period with specific psychosocial challenges and specific changes in the brain that increase the probability of the onset of both psychosis and substance abuse, in predisposed people. In vulnerable adolescents it is proposed that an excessive pruning of dopaminergic neurones leads to mesocortical hypofrontality causing anhedonia and dysphoria. At the same time, anhedonia and dysphoria are important risk factors for the development of substance abuse. In turn, hypofrontality leads to a reduction in mesocortical feedback inhibition of the mesolimbic system resulting in aberrant salience and positive symptoms. Finally, the development of aberrant salience plays a role in both psychoses and craving. CONCLUSION: Attention should be paid to the interaction of drug abuse and schizophrenia and an integrated treatment is needed. Dysphoria and anhedonia in schizophrenic adolescents are important factors in treatment with antipsychotic medication, both in terms of patient satisfaction and in the prevention of substance abuse.

Adolescence, schizophrenia and drug abuse: a window of vulnerability. Publishing Authors By Initials

L van Nimwegen,L de Haan,N van Beveren,W van den Brink,D Linszen,

For similar disorders of environmental origin: substance-related disorders research abstracts see: disorders of environmental origin: substance-related disorders research

PUBMED ID PMID:

MEDLINE DATE:

Adolescence, schizophrenia and drug abuse: a window of vulnerability. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Acta psychiatrica Scandinavica. Supplementum

VOLUME:

Page Numbers: 35-42

Journal Abbreviation:

ISSN: 0065-1591

DAY: 15

MONTH: 02

YEAR: 2005

Adolescence, schizophrenia and drug abuse: a window of vulnerability. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370365

Adolescence, schizophrenia and drug abuse: a window of vulnerability. Keywords Mesh Terms:

KEYWORDS: Substance-Related Disorders

MESH TERMS: epidemiology

Chemical & Substance for Abstract: Adolescence, schizophrenia and drug abuse: a window of vulnerability. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Adolescence, schizophrenia and drug abuse: a window of vulnerability.

AFFILIATION: Department of Psychiatry, Academical Medical Center, University of Amsterdam, Amsterdam, Netherlands. l.j.vannimwegen@amc.uva.nl

Country: Denmark

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Psychiatr Scand Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Adolescence, schizophrenia and drug abuse: a window of vulnerability Related Publications

• A meta-analysis of P50 studies in patients with schizophrenia and relatives: Differences in methodology between research groups.
• A quantitative measure for expressed emotion.
• Adolescence, schizophrenia and drug abuse: a window of vulnerability.
• Antisaccade deficit is present in young first-episode patients with schizophrenia but not in their healthy young siblings.
• Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.
• Failure to find p50 suppression deficits in young first-episode patients with schizophrenia and clinically unaffected siblings.
• Genetic variation in COMT and PRODH is associated with brain anatomy in patients with schizophrenia.
• Improvement of Subjective Well-being and Enduring Symptomatic Remission, A 5-Year Follow-up of First Episode Schizophrenia.
• Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis.
• Response to letter: "Lack of blinding in gating studies".
• Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up.
• White matter fibertracking in first-episode schizophrenia, schizoaffective patients and subjects at ultra-high risk of psychosis.